Lymphoma Rounds: New England

Westin Copley Place Hotel (click here for directions)
10 Huntington Avenue
Boston, MA 02116

Wednesday, February 6, 2019
6:00 PM – 8:30 PM

PROGRAM CO-CHAIRS

Robin M. Joyce, MD, MDivRobin Joyce, MD
Beth Israel Deaconess Medical Center

Jeremy S. Abramson, MD, MScJeremy Abramson, MD, MSc
Massachusetts General Hospital Cancer Center

Tarun Kewalramani, MD
Lahey Hospital and Medical Center

This program is free for healthcare professionals; however, pre-registration is required. Food and refreshments will be provided for all registered participants.

Please note: Only representatives from supporting pharmaceutical companies are invited to register. If your company is interested in becoming a Lymphoma Rounds supporter please contact Piper Harmon, LRF, at pharmon@lymphoma.org.  Exhibit opportunities are also available, however, space is limited.

Companies that have secured a national exhibit sponsorship for Lymphoma Rounds must still rsvp by emailing Piper Harmon (pharmon@lymphoma.org) at least one week before the program to confirm their attendance. Otherwise, an exhibit table will not be guaranteed.

REGISTER TODAY

ABOUT THE PROGRAM
The Lymphoma Research Foundation’s New England Lymphoma Rounds program provides a forum for healthcare professionals to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. Participants will network, share best practices and learn the latest information on new therapies and advances in the management of lymphoma through interactive case studies presented by lymphoma experts in the New England area.

At the conclusion of this educational activity, the participant should be better able to:

  • Summarize the latest developments in lymphoma diagnosis, treatment and management.
  • Apply best practices for treating lymphoma patients.
  • Inform patients about potential clinical trial opportunities.
  • Establish a network of health care professionals who work with lymphoma patients.
Other dates in the 2018-19 New England Rounds series:

  • Wednesday, April 10, 2019

New England Lymphoma Rounds Steering Committee

Baystate Medical Center
Armen Asik, MD
Beth Israel Deaconess Medical Center
Jon Arnason, MD
Robin Joyce, MD
Boston University School of Medicine
J. Mark Sloan, MD
Brown University School of Medicine/Rhode Island
Adam Olszewski, MD
Dana-Farber Cancer Institute
Jorge Castillo, MD
Ann LaCasce, MD
Dartmouth–Hitchcock Medical Center
Elizabeth Bengtson, MD
Erick Lansigan, MD
Lahey Hospital and Medical Center
Tarun Kewalramani, MD
Massachusetts General Hospital Cancer Center
Jeremy Abramson, MD, MSc
Jeffrey Barnes, MD, PhD
Tufts University Cancer Center
Andreas Klein, MD
UMass Memorial Medical Center
Jan Cerny, MD, PhD, FACP
Muthalagu Ramanathan, MD
University of Vermont College of Medicine
Julian Sprague, MD, PhD
Yale University School of Medicine
Francine Foss, MD

Joint Providership Statement

This activity has been planned and implemented in accordance with the Accreditation Requirements and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and the Lymphoma Research Foundation.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Statement

The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit (s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Sponsors
Lymphoma Research Foundation and the University of Nebraska Medical Center, Center for Continuing Education

This activity is supported by educational grants from:

AbbVie Inc., Celgene Corporation, Genentech, Novartis, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., Seattle Genetics, Inc., TG Therapeutics, Inc. and Verastem Oncology